BRC-002 is under clinical development by Biopharmaceutical Research and currently in Phase I for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy). According to GlobalData, Phase I drugs for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BRC-002 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BRC-002 overview

BRC-002 is under development for the treatment of complex regional pain syndrome (CRPS). The drug candidate is a cannabidiolic (CBD) formulation, naturally biosynthesized within the Cannabis sativa L. plant as acidic forms of CBD (cannabidiolic acid (CBDA), THC (tetrahydrocannabinolic acid (THCA) and other minor cannabinoids. It is administered through oral route in the form of solution.

Biopharmaceutical Research overview

Biopharmaceutical Research is a specialty pharmaceutical manufacturing company that develops cannabinoid therapeutic medicines designed to address underserved neurological and inflammatory diseases. The company is headquartered in Castroville, California, the US.

For a complete picture of BRC-002’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.